Popular on s4story
- Post-Traditional Career Expert Sandra Buatti-Ramos Receives 2025 Top Career Coach Recognition - 333
- The Office of Count Jonathan of Aquitaine Establishes Centre for Education and Diplomacy - 312
- Bookmakers Review: Joe Rogan Favored to Win Inaugural 2025 Golden Globes Podcast of the Year - 289
- The 2025 "Aizu Festival" in Aizu Wakamatsu City will be held September 19–21 - 289
- Ubleu Crypto Group Achieves FinCEN Registration and Colorado Incorporation, Accelerating U.S. Market Entry - 285
- New Urban Fantasy Series 'Secret Empires' Brings Ancient Magic and Hidden Wars to Life - 283
- Iterators Named Preferred Accessibility Testing Vendor by MIT - 282
- Memoir Surge and Publishing Innovation: Independent Houses Lead the Next Chapter of Literary Culture - 224
- Sober.Buzz Adds Second Podcast, "Spreading the Good BUZZ" Guest List Grows, Numbers Continue Growing Globally, All While Josh and Heidi Tied the Knot - 210
- Love Death + Explosives: Thomas Pynchon's Polipsychology | An Essay by Michael Finney - 210
Similar on s4story
- The Learning Circle Childcare Centre – South Surrey Campus Currently Enrolling for September & Fall
- New Leadership Model – Never Fire Anyone – Released Today
- IOTAP Named to 2025 Inc. 5000 List of America's Fastest-Growing Private Companies
- $5 - $20 Million in Sales for 2026; $25 - $40 Million for 2027 Projected with NASA Agreements; New MOU Signed to Improve Solar Tech in Space
- Portland Med Spa Expands Service Offerings with Latest Aesthetic Technologies
- OddsTrader Projects Three Potential Elimination Games in Week 1 of College Football
- The Squires Group Becomes a Workday Partner
- 500% Increase in Revenue for Q2 with Acquisition Plans Including UK Telecom 3D Design/Modeling Company for Global AI Drone & Quantum Computing Leader
- K2 Integrity and Rafidain Bank Launch Strategic Partnership to Strengthen Financial Integrity
- Joint Venture for Expansion Into Asset-Backed Real Estate; $100 Million Initiative via Offering of Shares at Over $4 for Digital Assets: $OFAL
Circular Genomics Receives $250K Investment from the Alzheimer's Drug Discovery Foundation (ADDF) to Advance First-in-Class Circular RNA Blood-Based Biomarker Tests for the Early Detection of Alzheimer's Disease
S For Story/10664771
SAN DIEGO, July 8, 2025 ~ Circular Genomics, Inc. has received a significant investment of $250,000 from the Alzheimer's Drug Discovery Foundation (ADDF) through its Diagnostics Accelerator (DxA) program. This investment will support further research on Circular Genomics' circRNA blood-based biomarkers for diagnosing and predicting the progression of Alzheimer's disease (AD).
As a global leader in circular RNA (circRNA) biomarkers for precision neurology and psychiatry, Circular Genomics is dedicated to developing the first blood-based tests that utilize circRNA to enable personalized diagnosis and treatment for complex neurological and psychiatric conditions, such as AD.
The investment, titled "Alzheimer's Disease Specificity and Sensitivity Analyses of circRNA Blood Markers," will fund research conducted in partnership with Carlos Cruchaga, PhD, Director of the NeuroGenomics and Informatics Center at Washington University of Medicine in St. Louis. The project aims to further study the potential of circRNA biomarkers to improve the diagnosis of AD and distinguish it from other dementias, providing clarity for patients and their healthcare providers.
More on S For Story
"We are honored to receive this investment from the ADDF as we continue to advance our suite of circRNA-based tools aimed at addressing the need for reliable diagnosis and prognosis for neurological conditions such as Alzheimer's," said Nikolaos Mellios, MD, PhD, Co-founder and Chief Scientific Officer of Circular Genomics. "Our goal is to transform the diagnostic and treatment journey for patients by enabling earlier detection, better patient stratification, and more personalized clinical management of the disease."
Dr. Cruchaga, a renowned expert in neurogenomics and biomarker discovery, also expressed excitement about this collaboration: "CircRNA biomarkers offer an exciting and promising approach for improving diagnostic accuracy and advancing personalized care for Alzheimer's. I'm looking forward to working with Circular Genomics to progress this innovative technology with the goal of improving outcomes for individuals at risk of AD through an earlier and more accurate diagnosis."
CircRNAs have been shown to play important roles in brain development, maturation, function, and aging, and have been linked to many neurological and psychiatric disorders. Their abnormal expression in pathological states makes them potential diagnostic and predictive biomarkers for numerous brain disorders. While circRNAs are mainly expressed in the brain, they can also be measured in blood, providing a window into overall brain health.
More on S For Story
The research funded by this investment will further quantify and characterize blood brain-derived circRNA biomarkers to create best-in-class tools for predicting AD's progression and enabling a more accurate diagnosis.
According to Howard Fillit, MD, Co-Founder and Chief Science Officer at the ADDF, "Circular Genomics' work represents the type of innovative science needed to transform how we detect and diagnose Alzheimer's disease." He added that by investing in accessible and scalable biomarker technologies like this one, they aim to accelerate earlier and more accurate diagnosis, which is a critical step towards treating Alzheimer's with precision medicine.
The DxA program is a $100 million global research initiative aimed at fast-tracking the development of biomarkers and diagnostic tools for the detection and diagnosis of Alzheimer's disease and related dementias. This investment from ADDF will undoubtedly support Circular Genomics' mission to improve outcomes for individuals at risk of AD through earlier detection and personalized care.
As a global leader in circular RNA (circRNA) biomarkers for precision neurology and psychiatry, Circular Genomics is dedicated to developing the first blood-based tests that utilize circRNA to enable personalized diagnosis and treatment for complex neurological and psychiatric conditions, such as AD.
The investment, titled "Alzheimer's Disease Specificity and Sensitivity Analyses of circRNA Blood Markers," will fund research conducted in partnership with Carlos Cruchaga, PhD, Director of the NeuroGenomics and Informatics Center at Washington University of Medicine in St. Louis. The project aims to further study the potential of circRNA biomarkers to improve the diagnosis of AD and distinguish it from other dementias, providing clarity for patients and their healthcare providers.
More on S For Story
- Nextnewbooks.com - No Sign-ups Or Logins Required
- Romance's Next Big Voice? Thia Finn Advances in Prestigious Mamaw Namid Romance Awards
- Minecraft: A Glitch in Time (Diary of a Minecraft Zombie: CHRONICLES OF CHARLES AND TINA)
- Birch Tree Publishing Launch: Jane Austen's Elinor and Marianne (The Jane Austen Dynasty)
- The Learning Circle Childcare Centre – South Surrey Campus Currently Enrolling for September & Fall
"We are honored to receive this investment from the ADDF as we continue to advance our suite of circRNA-based tools aimed at addressing the need for reliable diagnosis and prognosis for neurological conditions such as Alzheimer's," said Nikolaos Mellios, MD, PhD, Co-founder and Chief Scientific Officer of Circular Genomics. "Our goal is to transform the diagnostic and treatment journey for patients by enabling earlier detection, better patient stratification, and more personalized clinical management of the disease."
Dr. Cruchaga, a renowned expert in neurogenomics and biomarker discovery, also expressed excitement about this collaboration: "CircRNA biomarkers offer an exciting and promising approach for improving diagnostic accuracy and advancing personalized care for Alzheimer's. I'm looking forward to working with Circular Genomics to progress this innovative technology with the goal of improving outcomes for individuals at risk of AD through an earlier and more accurate diagnosis."
CircRNAs have been shown to play important roles in brain development, maturation, function, and aging, and have been linked to many neurological and psychiatric disorders. Their abnormal expression in pathological states makes them potential diagnostic and predictive biomarkers for numerous brain disorders. While circRNAs are mainly expressed in the brain, they can also be measured in blood, providing a window into overall brain health.
More on S For Story
- Antoine Maurice King Reaches #1 on Amazon with Think Like ChatGPT
- New Ownership, Same Heart: Jimmy & Jennifer Jhanda Take The Reins At Primos
- "Echoes in Green: The Big Yellow Sun" by Edward Forde Hickey is published
- THE LEAGUE: Where Basketball Meets Culture in the Heart of LA — Played at The Surgeon
- Integris Composites Joins Pacific Future Forum in Tokyo
The research funded by this investment will further quantify and characterize blood brain-derived circRNA biomarkers to create best-in-class tools for predicting AD's progression and enabling a more accurate diagnosis.
According to Howard Fillit, MD, Co-Founder and Chief Science Officer at the ADDF, "Circular Genomics' work represents the type of innovative science needed to transform how we detect and diagnose Alzheimer's disease." He added that by investing in accessible and scalable biomarker technologies like this one, they aim to accelerate earlier and more accurate diagnosis, which is a critical step towards treating Alzheimer's with precision medicine.
The DxA program is a $100 million global research initiative aimed at fast-tracking the development of biomarkers and diagnostic tools for the detection and diagnosis of Alzheimer's disease and related dementias. This investment from ADDF will undoubtedly support Circular Genomics' mission to improve outcomes for individuals at risk of AD through earlier detection and personalized care.
Filed Under: Business
0 Comments
Latest on S For Story
- Shincheonji Tanzania Church Holds Revelation Bible Exam with Local Pastors and Believers
- Portland Med Spa Expands Service Offerings with Latest Aesthetic Technologies
- Growth Acceleration via Strategic Reverse Split After $10 Million Acquisition for Concerts.com and TicketStub.com; AI Powered Sports/Entertainment Co
- Hollywood Casting Director's Book Hits #1 on Amazon Before Release
- OddsTrader Projects Three Potential Elimination Games in Week 1 of College Football
- Century Fasteners Corp. Exhibiting at the 2025 International Fastener Expo
- Canvas Cloud AI Launches to Transform Cloud Education From Memorization to Mastery
- The Squires Group Becomes a Workday Partner
- Cuesta College Writers Conference Returns Sept. 26–27 With Master Classes and 50 Workshops
- Windsor Cancer Survivor Inspires with New Book, Cancer Heroes
- Book Crew Podcast Launches Website and Goes Wide
- From Vernon Hills to Mensa Before Kindergarten
- PermianMuseum.com adds Interstellar Visitor Video Gallery
- SOBREO Elixirs Debut in New York City, Defining a New Era in Inclusive Hospitality
- Allen Field to Showcase Sustainable Paper Handle Applicator at PACK EXPO Las Vegas 2025
- Laughter, Magic & Mayhem Take Over Las Vegas At Two Hot Locations! Delirious Comedy Club & House of Magic Bring Nonstop Entertainment
- Pascal Bouquillard Releases New Dystopian Novel - Eden: The Final Solution
- New Sci-Fi Crime Novel Immerses Readers in an Increasingly Divided America
- 500% Increase in Revenue for Q2 with Acquisition Plans Including UK Telecom 3D Design/Modeling Company for Global AI Drone & Quantum Computing Leader
- K2 Integrity and Rafidain Bank Launch Strategic Partnership to Strengthen Financial Integrity